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Introduction
The latest analysis by the World Health Organization (WHO) demonstrates that the prevalence and incidence of syphilis continue to be high worldwide. Based on data collected between 2005 and 2012, regional prevalence varies between 0.2% and 1.8% and regional incidence varies between 0.9 and 4.4 cases per 1,000 persons (women or men); corresponding pooled global figures are 0.5% and 1.5 cases per 1,000 persons (women or men) respectively. 1 Syphilis prevalence and incidence remain highest in the African region, but have been rising in high income countries since approximately 2000.
One comprehensive review shows a significant increase in the syphilis notification rates in 23 of 27 high-income countries across North America, Europe and the Asia-Pacific Region, and highlights that this increase is due primarily to an increasing number of infections among men who have sex with men (MSM). 2 An uncommon, but serious manifestation of syphilis is uveitis (or inflammation inside the eye). 3 Surveillance data have provided an estimated risk of "ocular syphilis" -almost always presenting as uveitis -as just 0.6% to 2.7% of total infections. [4] [5] [6] However, the vision is frequently impacted in this condition: in the largest series published to date, including 85 persons from The Netherlands, 58.8% presented with reduction in vision to a level that typically limits driving (Snellen visual acuity < 6/12) and 29.4% suffered blindness (Snellen visual acuity < 6/60). 7 Current studies from the United States, 6, 8 Western Europe 9, 10 and Brazil 11 suggest syphilitic uveitis is increasing in prevalence and incidence, in parallel with the systemic infection.
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Consistent with increasing numbers of individuals suffering from syphilitic uveitis, multiple articles are presently being published about cohorts of patients with the condition. In the last 5 years alone, multiple independent studies from countries in the Americas, Western Europe and Australasia have reported on different clinical subjects relating to this form of uveitis, including regional epidemiology, ophthalmic features, ocular and systemic diagnostics, anti-microbial drug and corticosteroid treatments, and prognosis. 5, 7, 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Recently a group of 103 clinicians, specializing in the management of uveitis and based in 34 nations, came together as the International Ocular Syphilis Study Group to provide a global perspective of current practice patterns for syphilitic uveitis.
This article presents the collective experience of this group on clinical presentations and outcomes, as well as the preferred approach to investigation and treatment.
Materials and Methods
In July 2017, a subset of the membership of the International Ocular Inflammation Society (IOIS) formed the International Ocular Syphilis Study Group. The IOIS is a global scientific society, which is dedicated to the study of inflammatory eye diseases. At the time of this project, the IOIS membership totalled 268 clinicians and scientists: 103 clinical members joined the Study Group, which aimed to establish current practice patterns in the management of syphilitic uveitis. These members were based in the Supplementary Table 1 . For 73.8% of Study Group members (n = 76 of 103), the most frequent referral of a patient with syphilitic uveitis was from a fellow ophthalmologist who had identified uveitis, but not determined the cause. Some members reported other frequent routes for 7 their referrals, including: from another ophthalmologist with the diagnosis of syphilitic uveitis (n = 3, 2.9%); from a non-ophthalmologist health practitioner with the diagnosis of syphilis (n = 2, 1.9%); and HIV-positive individuals requesting ophthalmic screening (n = 7, 6.8%). Patients with uveitis most commonly presented to Study Group members (n = 102) during the secondary stage of syphilis (n = 41, 40.2%), followed by latent and tertiary stages (n = 23, 22.6% and n = 26, 25.5%, respectively), and the primary stage (n = 3, 2.9%). Following the Standardization of Uveitis Nomenclature anatomic classification, 24 102 members reported the form of syphilitic uveitis they managed most frequently was posterior or pan-uveitis (n = 62, 60.8% or n = 23, 22.5%, respectively), while anterior and intermediate uveitis were less often identified as the most frequently treated form (n = 4, 3.9% and n = 2, 2.0%, respectively). Study Group members encountered multiple ocular complications in their practices of syphilitic uveitis, including most commonly, optic neuropathy (n = 69 of 100 members, 68.3%), cystoid macular oedema (n = 51, 50.5%) and posterior synechiae (n = 51, 50.5%). Routes of referral and clinical presentations of syphilitic uveitis are presented in Table 1 . Abbreviations: PCR = polymerase chain reaction, CSF = cerebrospinal fluid, HIV = human immunodeficiency virus *Other situations included: recommendation by co-managing internist; posterior eye involvement; neurological symptoms; and cost.
Results

Members of the
A majority of Study Group members (n = 64 of 103, 62.1%) referred patients with syphilitic uveitis to an infectious disease physician for antibiotic treatment, although some ophthalmologists (n = 25, 24.3%) prescribed these drugs themselves based on their own expertise or the advice of an infectious disease specialist. Most members treated their patients with different forms of penicillin, including intravenous aqueous crystalline penicillin G (n = 63, 61.8%), and intramuscular benzathine penicillin G (n = 25, 24.5%) and procaine penicillin G (n = 2, 2.0%). A small number preferred to treat with other antibiotics, including intravenous ceftriaxone (n = 7, 6.9%) and oral doxycycline (n = 1, 1.0%). Treatment was almost always continued for 10 to 14 days or longer (n = 63, 66.3% and 28, 29.5% of 95 members, respectively). Of 102 members, 32 (31.4%) routinely prescribed adjunctive corticosteroid therapy, and 68 (66.7%) prescribed this therapy for selected patients. Corticosteroids were given topically (n =70 of 100 members, 70.0%), by local injection (n = 16, 16.0%) and/or systemically (n = 82, 82.0%). When adjunctive systemic corticosteroid therapy was used, this was most often initiated during, but after the start of antibiotics (n = 45 of 82 members, 54.9%).
However, 14 members (17.1%) started the corticosteroid at the same time as the antibiotic; 4 members (4.9%) started the corticosteroid after the course of antibiotic; and 19 members (23.1%) adjusted the timing of corticosteroid treatment depending on the clinical situation. The treatment of syphilitic uveitis is described in Table 3 . to them with uveitis. The approach to follow-up and prediction of the outcome of syphilitic uveitis are presented in Table 4 . 
Discussion
Syphilitic uveitis is re-emerging internationally, in parallel with the increasing incidence of the systemic infectious disease. 6, 8, 25 We present a description of current practice Complications of syphilitic uveitis are protean, affecting both anterior and posterior eye, and visually significant. In particular, cystoid macular oedema and optic neuropathy, identified by one-half and two-thirds of members, respectively, are well-established causes of vision loss that may be irreversible in patients with uveitis. 28 Study Group members rely on serologic testing to diagnose syphilis as the cause of uveitis; analysis of intraocular samples by PCR is seldom utilized. A diagnostic approach that has been promoted by uveitis specialists for several decades involves simultaneous testing for non-treponemal and treponemal antigens, rather than the traditional algorithm of a non-treponemal test, followed by treponemal test if the former is positive. 29 This approach has been taken to avoid falsely negative non-treponemal tests, particularly early or late in the course of the infection, when uveitis may first present.
Following recent introduction of automated, low-cost treponemal immunoassays, many diagnostic laboratories are adopting a reverse testing algorithm, i.e., treponemal test followed by non-treponemal test, when the former is positive. 30 The CDC recommends ocular syphilis be managed according to their guidelines for neurosyphilis. 31 That recommendation is 10 to 14 days of treatment with intravenous aqueous penicillin G, intramuscular procaine penicillin G (with oral probenecid) or, in the case of penicillin allergy, intravenous ceftriaxone. A majority of Study Group members liaise with an infectious disease physician to treat their patients and follow this medical approach. Addition of corticosteroid has been suggested to avoid a Jarisch-Herxheimer reaction, which is the inflammatory response that often accompanies initiation of antimicrobial treatment in syphilis 33 and may exacerbate uveitis. 34 Almost all Study Group members prescribe adjunctive corticosteroid, which typically is delivered systemically or in the form of eye drops. The preference for these delivery routes is consistent with the difficulty of removing locally injected corticosteroid in the event of a complication, and with the recent report of delayed resolution of syphilitic uveitis in patients who receive local corticosteroid injections. 19 Syphilitic uveitis causes long-term visual disability in a significant number of persons:
among one cohort of patients with ocular syphilis, who were treated and followed at Johns Hopkins School of Medicine, and described in detail, one in 5 eyes lost visual acuity to a level below 20/40, which prohibits driving in many countries. 14 several studies. 7, 17, 19 Patient-related factors were identified as one common reason for a delay in diagnosis. However, syphilitic uveitis is a great masquerader, and lack of recognition was identified as a major issue in delayed diagnosis. A related consideration was failure to order serologic testing for syphilis.
In summary, we have presented a description of practice patterns for syphilitic uveitis.
One potential limitation of our work relates to participation bias, since Study Group members came from one professional society, albeit the largest international society with specific interest in inflammatory eye disease. Another potential limitation stems from the fact that the field is rapidly evolving as syphilis re-emerges and new 18 management approaches are applied. For example, within a relatively short period, more members may embrace PCR testing of ocular fluid, as is being applied routinely in more common intraocular infections. 35 Despite these limitations, our work presents a unique, current and comprehensive description of the management of syphilitic uveitis by a large and international group of ophthalmologists who specialize in the treatment of inflammatory eye disease. Arguably our most important observation is the role of syphilis serologic testing in the timely diagnosis of syphilitic uveitis. Over 80% of Study Group members test any patient who presents with uveitis for syphilis.
